Related Experiment Video
Updated: Nov 13, 2025
07:16
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
Published on: November 30, 2022
3.9K
COVID-19 pneumonia: do not leave the corticosteroids behind!
Simone Mornese Pinna1, Silvia Scabini1, Silvia Corcione1
1Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.
Future Microbiology
|March 12, 2021
Summary
Corticosteroids (CS) can help manage COVID-19 lung injury by modulating inflammation. Optimal timing and dosage are key, with early high-dose, short-term CS showing promise in the inflammatory phase.
Area of Science:
- Pulmonology
- Immunology
- Virology
Background:
- Host inflammatory response is critical in SARS-CoV-2 lung injury progression.
- Corticosteroids (CS) are used as immunomodulators, but optimal use in COVID-19 is unclear.
- Early CS may increase viral replication, while late use might not prevent alveolar damage.
Purpose of the Study:
- To define the therapeutic role of corticosteroids in COVID-19 infection.
- To identify patient characteristics that may benefit from CS administration.
- To explore the impact of CS timing, dosage, and type on COVID-19 outcomes.
Main Methods:
- Review of existing literature on corticosteroid use in COVID-19.
- Analysis of patient data to identify predictors of response to CS.
- In vitro studies examining the effect of inhaled CS on SARS-CoV-2 replication.
Main Results:
- Short, high-dose CS administration in the early inflammatory phase showed favorable outcomes.
- Some inhaled corticosteroids demonstrated in vitro inhibition of SARS-CoV-2 replication.
- The optimal timing, dosage, and molecular type of CS remain to be fully elucidated.
Conclusions:
- Corticosteroids have a defined place in managing COVID-19, particularly during the inflammatory phase.
- Identifying specific patient populations who benefit from CS is crucial for effective treatment.
- Further research is needed to optimize CS therapy for COVID-19 patients.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
533
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
533
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.2K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.2K
01:28Pneumonia IV: Management
564
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
564
01:29Pneumonia II: Pathophysiology
1.6K
The pathophysiology of pneumonia involves the following steps:
1.6K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
289
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
289
01:20COPD: Pathogenesis and Clinical Features
1.5K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.5K